Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Agenus announced early Phase 2 results from the dMMR colon cancer cohort of NEOASIS, an investigator-initiated study sponsored by the Netherlands Cancer Institute. The study evaluates botensilimab plus balstilimab before surgery; the provided text does not include efficacy or safety results.

Analysis

The investable information is the dataset, not the “early results” label: the release excerpt supplies no response rate, pathological complete response, safety, follow-up, or comparator. Without those, the update cannot support a change to BOT/BAL’s probability of technical or commercial success. The pre-surgery setting may make pathological response a useful early signal, but a small investigator-initiated cohort is not equivalent to randomized evidence or a registrational read-through. Any immediate AGEN move is therefore more likely to reflect headline positioning than a defensible revision to long-term cash flows.

Over the next 1–3 months, the key catalyst is a fuller dataset with cohort size, efficacy denominators, durability, and immune-related toxicity; safety matters particularly when combining checkpoint inhibitors before surgery, where treatment complications could affect surgical timing. Over 6–18 months, the question is whether results replicate and translate into a defined path toward larger controlled studies. Established checkpoint-inhibitor options in dMMR disease create a high efficacy bar and limit the value of activity without comparative context. A strong, durable response signal with manageable toxicity could improve the platform’s strategic value; weak or selectively reported results, serious toxicity, or no clear development path would leave little fundamental support for enthusiasm. No valuation, liquidity, or consensus data are supplied, so do not infer a mispricing or financing catalyst.

Key Decisions for Investors

• No directional trade on this excerpt alone. Treat AGEN as a high-binary-event exposure and avoid sizing from the headline; the evidence disclosed here is insufficient to quantify probability-adjusted upside.
• Set a data alert for the complete NEOASIS cohort results: verify patient count, response and pathological-response definitions, follow-up, duration, grade and type of toxicity, surgical outcomes, and whether results are independently presented or peer reviewed.
• Reassess only if the efficacy signal is clinically meaningful and durable with acceptable perioperative safety, and the company outlines a credible controlled-study path. Those are the conditions for considering a long catalyst position; neither is established in the supplied excerpt.
• Falsify a bullish read-through if fuller reporting shows limited or short-lived activity, material immune toxicity or surgery delays, or failure to advance into a controlled study. Monitor subsequent AGEN guidance and financing disclosures before treating any trial signal as value-accretive.